Cost-effectiveness of nonavalent HPV vaccination in the Netherlands
ABSTRACTBackground A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.Research design and methods We compared the public health and economic benefits of 2vHPV- and 9vHPV-based vaccination strategies in the Netherlands over 100 years using a validated deterministic dynamic transmission metapopulation model.Results Compared to 2vHPV, the 9vHPV strategy averted an additional 3,245 cases of and 825 deaths from 9vHPV-strain-attributable cancers, 4,247 cases of and 190 deaths from recurrent respiratory papillomatosis (R... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2024 |
Reihe/Periodikum: | Expert Review of Vaccines, Vol 23, Iss 1, Pp 312-323 (2024) |
Verlag/Hrsg.: |
Taylor & Francis Group
|
Schlagwörter: | Cost-effectiveness modeling / health economics / HPV vaccination / human papilloma virus / netherlands / Internal medicine / RC31-1245 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-29169118 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1080/14760584.2024.2322543 |